- Conditions
- Cystic Fibrosis
- Interventions
- azithromycin, placebo, Tobramycin solution for inhalation
- Drug
- Lead sponsor
- Bonnie Ramsey
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 45
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 11,325
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure; With Decompensation
- Interventions
- Danger Signs of Heart Failure Videos
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 8
- States / cities
- Macon, Georgia • Cleveland, Ohio • Garfield Heights, Ohio + 4 more
- Conditions
- Vitreoretinal Traction Syndrome
- Interventions
- Plasmin
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Preterm Infants
- Interventions
- Experimental human milk fortifier, Control human milk fortifier
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- Up to 21 Days
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Diego, California • Tampa, Florida + 11 more
- Conditions
- Osteoporosis
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 65 Years to 89 Years · Female only
- Enrollment
- 7,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 50 more
- Conditions
- HIV-1 and Hepatitis C Co-Infection
- Interventions
- pioglitazone, peginterferon, ribavirin
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 48
- States / cities
- Orange, California • Palo Alto, California • Riverside, California + 41 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Sapacitabine, Decitabine
- Drug
- Lead sponsor
- Cyclacel Pharmaceuticals, Inc.
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
- Interventions
- IL13-PE38QQR, Surgery for placement, Radiation therapy, Temozolomide with radiation therapy
- Drug · Procedure
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- San Francisco, California • Charlotte, North Carolina • Durham, North Carolina + 3 more
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
- Interventions
- TransCon TLR7/8 Agonist, Pembrolizumab
- Drug
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
- Interventions
- RAYOS, Prednisone
- Drug
- Lead sponsor
- Ampel BioSolutions, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 15 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Tolvaptan MR, Tolvaptan IR, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- IMRT, Nivolumab
- Radiation · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- Positive FIT or Stool DNA Testing Follow up
- Interventions
- Patient navigator
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Age-Related Macular Degeneration
- Interventions
- OT-551, vehicle placebo
- Drug
- Lead sponsor
- Othera Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
- Conditions
- Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
- Interventions
- EsoCheck, EsoGuard
- Device · Diagnostic Test
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
- Conditions
- Arrhythmias, Cardiac
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2035
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Arteriosclerosis, Hypercholesterolaemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 132
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 63 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa capsules, Placebo capsules
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 168
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Blood Coagulation
- Interventions
- mgt of bleeding concerns/complications of oral anticoagulants
- Other
- Lead sponsor
- Hospital Quality Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
- Conditions
- Heart Arrhythmias
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative
- Interventions
- Lucitanib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 33
- States / cities
- Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more